Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

@article{Cortes2002MylotargCW,
  title={Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia},
  author={Jorge E. Cortes and Apostolia-Maria Tsimberidou and Ricardo Alvarez and Deborah A. Thomas and Miloslav E Beran and Hagop M Kantarjian and Elihu Estey and Francis J Giles},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2002},
  volume={50},
  pages={497-500}
}
Abstract Purpose. Mylotarg, a humanized anti-CD33 antibody linked to an antitumor antibiotic, is approved for the treatment of patients with relapsed acute myeloid leukemia (AML). Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML. Methods. MTA consisted of Mylotarg 9 mg/m2 intravenously (i.v.) over 2 h on day 1, ara-C 1 g/m2 over 2 h i.v. on days 1 through 5, and… CONTINUE READING